At EBMT 2025, Dr. Luca Vago delivered a compelling presentation titled “Mechanisms of Leukemia Relapse after Allogeneic Transplantation: From Biology to Treatment (and Back).” His talk focused on the intricate immunobiology of allo-HCT and the many hidden variables such as donor type and post-transplant interventions that influence relapse risk.
Dr. Vago stressed that allo-HCT is not a one-size-fits-all approach but rather a highly dynamic system. To better anticipate and prevent relapse, he called for the integration of real-life datasets and artificial intelligence to define biologically relevant risk factors. These insights could reshape how we design clinical trials, moving away from broad eligibility criteria toward targeted, time-sensitive interventions.
This forward-looking perspective paves the way for personalized strategies to minimize relapse and improve long-term transplant outcomes.
Thank you to Dr. Vago for highlighting the path forward in post-transplant relapse management.
